论文部分内容阅读
[目的]探讨普萘洛尔对血管瘤患儿血清血管内皮生长因子(VEGF)及其受体 VGFR1、VGFR2 表达水平的影响.[方法]选择 2014年 12 月至 2017 年 12 月本院收治的48例血管瘤患儿,所有患儿给予普萘洛尔口服(3 个月以下0.5 mg／kg,3～6 个月1 mg／kg,6 个月以上2 mg／kg,2 次／日,共计3 个月).记录患儿治疗前及治疗3 个月后静脉血 VEGF及其受体 VGFR1、VGFR2 水平,以超声测量观察组治疗前及治疗 3 月后肿瘤体积并进行疗效评价.[结果]治疗一个疗程后,患儿血清中 VEGF及其受体 VGFR1、VGFR2 蛋白水平和 mRNA表达水平均显著低于治疗前,差异有统计学意义(P ＜0.05).治疗后血管瘤体积为(0.29±0.09)cm3 显著低于治疗前的(0.78±0.15)cm3 ,差异有统计学意义(P ＜0.05).治疗后 Achauer疗效评定法评估治疗效果,其中优 20 例,良15 例,可7 例,差6 例,优良率为72.9%.[结论]普萘洛尔治疗血管瘤患儿临床效果较佳,其机制可能与下调血清VEGF及其受体 VGFR1、VGFR2 的表达水平有关.“,”[Objective]To investigate the effect of propranolol on the expression of VEGF and its receptorsVGFR1／VEGFR2 in serum of children with hemangioma.[Methods]From December 2014 to December 2017,48 children with hemangioma in our hospital were selected.All the children were given propranolol orally (0.5 mg／kg for less than 3 months,1 mg／kg for 3～6 months,2 mg／kg for more than 6 months,twice a day,a total of 3 months).The levels of VEGF and its receptors VGFR1／VEGFR2 ,were recorded before and 3 months after treatment.The tumor volume of the observation group before and 3 months after treatment was measured by ultrasound and the curative effect was evaluated.[Results]After one course of treatment,the levels of VEGF and its receptor VGFR1／VEGFR2 protein and mRNA expression in serum were significantly lower than those before treatment (P ＜0.05).The volume of hemangioma after treatment was (0.29 ± 0.09)cm3 ,which was signifi cantly lower than that before treatment (0.78 ± 0.15)cm3 ,the difference was statistically significant (P＜0.05). After treatment,Achauer method was used to evaluate the therapeutic effect,including 20 excellent cases,15 good cases,7 fair cases and 6 poor cases.The excellent and good rate was 72.9%.[Conclusion]The clinical effect of propranolol is better in children with hemangioma.The mechanism may be related to the downregulation of serum VEGF and its receptor VGFR1／VEGFR2 expression levels.